217 related articles for article (PubMed ID: 14669170)
1. Effect of pramlintide on A1C and body weight in insulin-treated African Americans and Hispanics with type 2 diabetes: a pooled post hoc analysis.
Maggs D; Shen L; Strobel S; Brown D; Kolterman O; Weyer C
Metabolism; 2003 Dec; 52(12):1638-42. PubMed ID: 14669170
[TBL] [Abstract][Full Text] [Related]
2. Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes.
Ratner RE; Want LL; Fineman MS; Velte MJ; Ruggles JA; Gottlieb A; Weyer C; Kolterman OG
Diabetes Technol Ther; 2002; 4(1):51-61. PubMed ID: 12017421
[TBL] [Abstract][Full Text] [Related]
3. Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients.
Hollander P; Maggs DG; Ruggles JA; Fineman M; Shen L; Kolterman OG; Weyer C
Obes Res; 2004 Apr; 12(4):661-8. PubMed ID: 15090634
[TBL] [Abstract][Full Text] [Related]
4. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial.
Ratner RE; Dickey R; Fineman M; Maggs DG; Shen L; Strobel SA; Weyer C; Kolterman OG
Diabet Med; 2004 Nov; 21(11):1204-12. PubMed ID: 15498087
[TBL] [Abstract][Full Text] [Related]
5. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial.
Hollander PA; Levy P; Fineman MS; Maggs DG; Shen LZ; Strobel SA; Weyer C; Kolterman OG
Diabetes Care; 2003 Mar; 26(3):784-90. PubMed ID: 12610038
[TBL] [Abstract][Full Text] [Related]
6. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes.
Whitehouse F; Kruger DF; Fineman M; Shen L; Ruggles JA; Maggs DG; Weyer C; Kolterman OG
Diabetes Care; 2002 Apr; 25(4):724-30. PubMed ID: 11919132
[TBL] [Abstract][Full Text] [Related]
7. Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets.
Hollander P; Ratner R; Fineman M; Strobel S; Shen L; Maggs D; Kolterman O; Weyer C
Diabetes Obes Metab; 2003 Nov; 5(6):408-14. PubMed ID: 14617226
[TBL] [Abstract][Full Text] [Related]
8. Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targets.
Ratner R; Whitehouse F; Fineman MS; Strobel S; Shen L; Maggs DG; Kolterman OG; Weyer C
Exp Clin Endocrinol Diabetes; 2005 Apr; 113(4):199-204. PubMed ID: 15891954
[TBL] [Abstract][Full Text] [Related]
9. Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin.
Riddle M; Frias J; Zhang B; Maier H; Brown C; Lutz K; Kolterman O
Diabetes Care; 2007 Nov; 30(11):2794-9. PubMed ID: 17698615
[TBL] [Abstract][Full Text] [Related]
10. Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study.
Aronne L; Fujioka K; Aroda V; Chen K; Halseth A; Kesty NC; Burns C; Lush CW; Weyer C
J Clin Endocrinol Metab; 2007 Aug; 92(8):2977-83. PubMed ID: 17504894
[TBL] [Abstract][Full Text] [Related]
11. Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus.
Singh-Franco D; Robles G; Gazze D
Clin Ther; 2007 Apr; 29(4):535-62. PubMed ID: 17617279
[TBL] [Abstract][Full Text] [Related]
12. Pramlintide improved measures of glycemic control and body weight in patients with type 1 diabetes mellitus undergoing continuous subcutaneous insulin infusion therapy.
Herrmann K; Frias JP; Edelman SV; Lutz K; Shan K; Chen S; Maggs D; Kolterman OG
Postgrad Med; 2013 May; 125(3):136-44. PubMed ID: 23748514
[TBL] [Abstract][Full Text] [Related]
13. Effect of pramlintide as an adjunct to basal insulin on markers of cardiovascular risk in patients with type 2 diabetes.
Wysham C; Lush C; Zhang B; Maier H; Wilhelm K
Curr Med Res Opin; 2008 Jan; 24(1):79-85. PubMed ID: 18031595
[TBL] [Abstract][Full Text] [Related]
14. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes.
Edelman S; Garg S; Frias J; Maggs D; Wang Y; Zhang B; Strobel S; Lutz K; Kolterman O
Diabetes Care; 2006 Oct; 29(10):2189-95. PubMed ID: 17003291
[TBL] [Abstract][Full Text] [Related]
15. Impact of Disease Duration on the Effects of Pramlintide in Type 1 Diabetes: A Post Hoc Analysis of Three Clinical Trials.
Herrmann K; Brunell SC; Li Y; Zhou M; Maggs DG
Adv Ther; 2016 May; 33(5):848-61. PubMed ID: 27071768
[TBL] [Abstract][Full Text] [Related]
16. Pramlintide as an adjunct to insulin in patients with type 2 diabetes in a clinical practice setting reduced A1C, postprandial glucose excursions, and weight.
Karl D; Philis-Tsimikas A; Darsow T; Lorenzi G; Kellmeyer T; Lutz K; Wang Y; Frias JP
Diabetes Technol Ther; 2007 Apr; 9(2):191-9. PubMed ID: 17425446
[TBL] [Abstract][Full Text] [Related]
17. Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin. The Pramlintide in Type 2 Diabetes Group.
Thompson RG; Pearson L; Schoenfeld SL; Kolterman OG
Diabetes Care; 1998 Jun; 21(6):987-93. PubMed ID: 9614619
[TBL] [Abstract][Full Text] [Related]
18. Diabetes distress and its association with clinical outcomes in patients with type 2 diabetes treated with pramlintide as an adjunct to insulin therapy.
Peyrot M; Rubin RR; Polonsky WH
Diabetes Technol Ther; 2008 Dec; 10(6):461-6. PubMed ID: 19049375
[TBL] [Abstract][Full Text] [Related]
19. Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes.
Riddle M; Pencek R; Charenkavanich S; Lutz K; Wilhelm K; Porter L
Diabetes Care; 2009 Sep; 32(9):1577-82. PubMed ID: 19502544
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and harms of the hypoglycemic agent pramlintide in diabetes mellitus.
Lee NJ; Norris SL; Thakurta S
Ann Fam Med; 2010; 8(6):542-9. PubMed ID: 21060125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
